---
document_datetime: 2025-12-02 06:42:07
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/palonosetron-hospira.html
document_name: palonosetron-hospira.html
version: success
processing_time: 0.0999069
conversion_datetime: 2025-12-28 15:31:46.138597
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Palonosetron Hospira

[RSS](/en/individual-human-medicine.xml/65971)

##### Withdrawn

This medicine's authorisation has been withdrawn

palonosetron Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Palonosetron Hospira](#news-on)
- [More information on Palonosetron Hospira](#more-information-on-palonosetron-hospira-577)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 8 April 2019, the marketing authorisation of Palonosetron Hospira (palonosetron) ceased to be valid in the European Union (EU). The cessation of validity is due to the fact that the marketing authorisation holder, Pfizer Europe MA EEIG, had not marketed Palonosetron Hospira in the EU since its initial marketing authorisation. In accordance with provisions of the sunset clause1, the marketing authorisation of the medicinal product lapsed as the product had not been marketed in any of the EU Member States within three years of its initial authorisation.

Pfizer Europe MA EEIG confirmed that the product had not been marketed due to commercial reasons. Palonosetron Hospira was granted marketing authorisation in the EU on 8 April 2016 for prevention of nausea and vomiting associated with cancer chemotherapy. The marketing authorisation was initially valid for a 5-year period.

Palonosetron Hospira is a generic medicine of Aloxi. There are other generic medicinal products of Aloxi authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Palonosetron Hospira is updated to indicate that the marketing authorisation is no longer valid.

Palonosetron Hospira : EPAR - Summary for the public

English (EN) (645.71 KB - PDF)

**First published:** 21/04/2016

**Last updated:** 08/04/2022

[View](/en/documents/overview/palonosetron-hospira-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-751)

български (BG) (714.67 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/bg/documents/overview/palonosetron-hospira-epar-summary-public_bg.pdf)

español (ES) (645.44 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/es/documents/overview/palonosetron-hospira-epar-summary-public_es.pdf)

čeština (CS) (700.5 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/cs/documents/overview/palonosetron-hospira-epar-summary-public_cs.pdf)

dansk (DA) (644.77 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/da/documents/overview/palonosetron-hospira-epar-summary-public_da.pdf)

Deutsch (DE) (646.19 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/de/documents/overview/palonosetron-hospira-epar-summary-public_de.pdf)

eesti keel (ET) (644.04 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/et/documents/overview/palonosetron-hospira-epar-summary-public_et.pdf)

ελληνικά (EL) (742.46 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/el/documents/overview/palonosetron-hospira-epar-summary-public_el.pdf)

français (FR) (645.76 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/fr/documents/overview/palonosetron-hospira-epar-summary-public_fr.pdf)

hrvatski (HR) (663.3 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/hr/documents/overview/palonosetron-hospira-epar-summary-public_hr.pdf)

italiano (IT) (644.63 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/it/documents/overview/palonosetron-hospira-epar-summary-public_it.pdf)

latviešu valoda (LV) (699.31 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/lv/documents/overview/palonosetron-hospira-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (666.63 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/lt/documents/overview/palonosetron-hospira-epar-summary-public_lt.pdf)

magyar (HU) (694.79 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/hu/documents/overview/palonosetron-hospira-epar-summary-public_hu.pdf)

Malti (MT) (699.89 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/mt/documents/overview/palonosetron-hospira-epar-summary-public_mt.pdf)

Nederlands (NL) (645.57 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/nl/documents/overview/palonosetron-hospira-epar-summary-public_nl.pdf)

polski (PL) (700.96 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/pl/documents/overview/palonosetron-hospira-epar-summary-public_pl.pdf)

português (PT) (645.19 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/pt/documents/overview/palonosetron-hospira-epar-summary-public_pt.pdf)

română (RO) (665.85 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/ro/documents/overview/palonosetron-hospira-epar-summary-public_ro.pdf)

slovenčina (SK) (699.65 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/sk/documents/overview/palonosetron-hospira-epar-summary-public_sk.pdf)

slovenščina (SL) (693.45 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/sl/documents/overview/palonosetron-hospira-epar-summary-public_sl.pdf)

Suomi (FI) (644.45 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/fi/documents/overview/palonosetron-hospira-epar-summary-public_fi.pdf)

svenska (SV) (645.24 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/sv/documents/overview/palonosetron-hospira-epar-summary-public_sv.pdf)

## Product information

Palonosetron Hospira : EPAR - Product Information

English (EN) (781.25 KB - PDF)

**First published:** 21/04/2016

**Last updated:** 08/04/2022

[View](/en/documents/product-information/palonosetron-hospira-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-943)

български (BG) (225.56 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/bg/documents/product-information/palonosetron-hospira-epar-product-information_bg.pdf)

español (ES) (796.73 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/es/documents/product-information/palonosetron-hospira-epar-product-information_es.pdf)

čeština (CS) (1.21 MB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/cs/documents/product-information/palonosetron-hospira-epar-product-information_cs.pdf)

dansk (DA) (791.76 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/da/documents/product-information/palonosetron-hospira-epar-product-information_da.pdf)

Deutsch (DE) (801.91 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/de/documents/product-information/palonosetron-hospira-epar-product-information_de.pdf)

eesti keel (ET) (781.47 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/et/documents/product-information/palonosetron-hospira-epar-product-information_et.pdf)

ελληνικά (EL) (1.48 MB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/el/documents/product-information/palonosetron-hospira-epar-product-information_el.pdf)

français (FR) (803.48 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/fr/documents/product-information/palonosetron-hospira-epar-product-information_fr.pdf)

hrvatski (HR) (798.68 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/hr/documents/product-information/palonosetron-hospira-epar-product-information_hr.pdf)

íslenska (IS) (797.16 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/is/documents/product-information/palonosetron-hospira-epar-product-information_is.pdf)

italiano (IT) (788.09 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/it/documents/product-information/palonosetron-hospira-epar-product-information_it.pdf)

latviešu valoda (LV) (1.23 MB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/lv/documents/product-information/palonosetron-hospira-epar-product-information_lv.pdf)

lietuvių kalba (LT) (799.33 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/lt/documents/product-information/palonosetron-hospira-epar-product-information_lt.pdf)

magyar (HU) (1.24 MB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/hu/documents/product-information/palonosetron-hospira-epar-product-information_hu.pdf)

Malti (MT) (1.29 MB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/mt/documents/product-information/palonosetron-hospira-epar-product-information_mt.pdf)

Nederlands (NL) (794.44 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/nl/documents/product-information/palonosetron-hospira-epar-product-information_nl.pdf)

norsk (NO) (786.4 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/no/documents/product-information/palonosetron-hospira-epar-product-information_no.pdf)

polski (PL) (1.24 MB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/pl/documents/product-information/palonosetron-hospira-epar-product-information_pl.pdf)

português (PT) (797.82 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/pt/documents/product-information/palonosetron-hospira-epar-product-information_pt.pdf)

română (RO) (793.56 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/ro/documents/product-information/palonosetron-hospira-epar-product-information_ro.pdf)

slovenčina (SK) (1.2 MB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/sk/documents/product-information/palonosetron-hospira-epar-product-information_sk.pdf)

slovenščina (SL) (1.25 MB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/sl/documents/product-information/palonosetron-hospira-epar-product-information_sl.pdf)

Suomi (FI) (787.3 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/fi/documents/product-information/palonosetron-hospira-epar-product-information_fi.pdf)

svenska (SV) (787.3 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/sv/documents/product-information/palonosetron-hospira-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IAIN/0005/G 12/12/2018

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Palonosetron Hospira : EPAR - All Authorised presentations

English (EN) (577.95 KB - PDF)

**First published:** 21/04/2016

**Last updated:** 08/04/2022

[View](/en/documents/all-authorised-presentations/palonosetron-hospira-epar-all-authorised-presentations_en.pdf)

[Other languages (22)](#file-language-dropdown-381)

български (BG) (640.77 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/bg/documents/all-authorised-presentations/palonosetron-hospira-epar-all-authorised-presentations_bg.pdf)

español (ES) (578.37 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/es/documents/all-authorised-presentations/palonosetron-hospira-epar-all-authorised-presentations_es.pdf)

čeština (CS) (620.16 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/cs/documents/all-authorised-presentations/palonosetron-hospira-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (600.91 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/da/documents/all-authorised-presentations/palonosetron-hospira-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (578.03 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/de/documents/all-authorised-presentations/palonosetron-hospira-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (583.91 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/et/documents/all-authorised-presentations/palonosetron-hospira-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (629.34 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/el/documents/all-authorised-presentations/palonosetron-hospira-epar-all-authorised-presentations_el.pdf)

français (FR) (578.15 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/fr/documents/all-authorised-presentations/palonosetron-hospira-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (658.15 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/hr/documents/all-authorised-presentations/palonosetron-hospira-epar-all-authorised-presentations_hr.pdf)

italiano (IT) (578.23 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/it/documents/all-authorised-presentations/palonosetron-hospira-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (622.5 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/lv/documents/all-authorised-presentations/palonosetron-hospira-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (611.18 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/lt/documents/all-authorised-presentations/palonosetron-hospira-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (605.35 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/hu/documents/all-authorised-presentations/palonosetron-hospira-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (628.27 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/mt/documents/all-authorised-presentations/palonosetron-hospira-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (586.98 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/nl/documents/all-authorised-presentations/palonosetron-hospira-epar-all-authorised-presentations_nl.pdf)

polski (PL) (620.45 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/pl/documents/all-authorised-presentations/palonosetron-hospira-epar-all-authorised-presentations_pl.pdf)

português (PT) (578.05 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/pt/documents/all-authorised-presentations/palonosetron-hospira-epar-all-authorised-presentations_pt.pdf)

română (RO) (603.33 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/ro/documents/all-authorised-presentations/palonosetron-hospira-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (619.58 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/sk/documents/all-authorised-presentations/palonosetron-hospira-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (629.74 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/sl/documents/all-authorised-presentations/palonosetron-hospira-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (581.51 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/fi/documents/all-authorised-presentations/palonosetron-hospira-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (586.64 KB - PDF)

**First published:**

21/04/2016

**Last updated:**

08/04/2022

[View](/sv/documents/all-authorised-presentations/palonosetron-hospira-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Palonosetron Hospira Active substance palonosetron hydrochloride International non-proprietary name (INN) or common name palonosetron Therapeutic area (MeSH)

- Nausea
- Vomiting
- Cancer

Anatomical therapeutic chemical (ATC) code A04AA05

### Pharmacotherapeutic group

Antiemetics and antinauseants

### Therapeutic indication

Palonosetron Hospira is indicated in adults for:

- the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy;
- the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

Palonosetron Hospira is indicated in paediatric patients 1 month of age and older for:

- the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

## Authorisation details

EMA product number EMEA/H/C/004069

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Pfizer Europe MA EEIG

Boulevard de la Plaine 17

Marketing authorisation issued 08/04/2016 Revision 4

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Palonosetron Hospira : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (675.47 KB - PDF)

**First published:** 09/03/2017

**Last updated:** 08/04/2022

[View](/en/documents/procedural-steps-after/palonosetron-hospira-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Palonosetron Hospira : EPAR - Public assessment report

Adopted

Reference Number: EMA/215640/2016

English (EN) (865.92 KB - PDF)

**First published:** 21/04/2016

**Last updated:** 08/04/2022

[View](/en/documents/assessment-report/palonosetron-hospira-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Palonosetron Hospira

Adopted

Reference Number: EMA/CHMP/131135/2016

English (EN) (629.46 KB - PDF)

**First published:** 26/02/2016

**Last updated:** 08/04/2022

[View](/en/documents/smop-initial/chmp-summary-opinion-palonosetron-hospira_en.pdf)

#### News on Palonosetron Hospira

[Clinical data for two more medicines now available online](/en/news/clinical-data-two-more-medicines-now-available-online) 01/02/2017

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 February 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-february-2016) 26/02/2016

#### More information on Palonosetron Hospira

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/search?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-1=1=EMEAHC0040690000) (initial marketing authorisation)

**This page was last updated on** 08/04/2022

## Share this page

[Back to top](#main-content)